



Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

November 13, 2024

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:

2024 Jefferies London Healthcare Conference

Presentation: Tuesday, November 19, 2024, at 10:00 a.m. GMT

Location: London, UK

Piper Sandler 36th Annual Healthcare Conference

Fireside Chat: Tuesday, December 3, 2024, at 11:30 a.m. ET

Location: New York, NY

Live webcasts of the presentations will be available [here](#) and in the investors section of the company's website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.

About Design Therapeutics

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company's GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington's disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:

Renee Leck

THRUST Strategic Communications

renee@thrustsc.com